-
Jan
The 2025 HitGen BIO Ecosystem Conference was held in Chengdu
-
Feb
DNA-Encoded Library Technology for Drug Discovery is officially published, co-edited by HitGen’s Guansai Liu, Jin Li and Purdue University Associate Professor Casey J. Krusemark
-
Apr
HitGen has sponsored the MBC 2025 Platinum Program, empowering biotech startups
-
Apr
The official website of Hitston has been officially launched, provide world-class CDMO services for small nucleic acid drugs
-
May
HitGen’s website has been officially upgraded, offering a one-stop solution from early discovery to IND-enabling studies
-
May
Delegation from UK Foreign, Commonwealth & Development Office Visited HitGen
-
Jun
HitGen has been listed on the "Top 20 Enterprises of the 2025 China CRO Outstanding Brand List"
-
Jun
HitGen Releases Its Inaugural Sustainability Report
-
Aug
HitGen Launches OpenDEL™ 5.0 – Boasting Expanded Chemical Diversity, Optional Macrocycle Library, Streamlined Workflows and Faster Access
-
Aug
HitGen has been awarded the title of "TOP20 Preclinical CRO Rankings for New Drugs in China 2025"
-
Sep
HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor
-
Sep
The "AI-enabled Innovation Consortium" participated by HitGen announced that it has successfully identified an innovative drug target for malignant tumors and officially entered the stage of molecular design and optimization
-
Oct
HitGen signed a framework cooperation agreement on in-depth integration of industry, academia and research with Yunnan University
-
Nov
HitGen announces the launch of the OpenDEL™ Community – a dedicated platform for drug discovery professionals passionate about DNA-encoded library (DEL) technology
-
Nov
HitGen Receives New Funding to Discover Novel Therapeutics for Underserved Diseases
-
Dec
The first HitGen Investor Open Day held in Chengdu
-
Dec
Main Structure of HitGen Global Drug R&D and Production Base (Phase I) Project Successfully Completed
-
Dec
HitGen-Backed Equity Investment Fund to Invest RMB40 Million for Controlling Stake in Moshang Intelligence, an AI Pharma Data Service Provider
-
Dec
HitGen has been honored as one of the "Top 100 Growing Listed Companies in China 2025"